|
Cephradine
Cephradine (Velosef)
Cephradine
(
SEF-rah-deen)
Pregnancy Category: B
Velosef
(Rx)
Classification:
Cephalosporin, first-generation
See Also:
See also
Anti-Infectives
[ and
Cephalosporins
][.
]
Action/Kinetics:
Similar to cephalexin. Rapidly absorbed PO or IM (30 min-2 hr); 60%-90% excreted after 6 hr.
Peak serum levels: PO, 8-24 mcg/mL after 30-60 min;
IM, 5.6-13.6 mcg/mL after 1-2 hr.
t
1/2: 42-80 min; 80%-95% excreted in urine unchanged.
Uses:
Oral. (1) Respiratory tract infections (tonsillitis, pharyngitis, lobar pneumonia) due to
Streptococcus pneumoniae and group A ß-hemolytic streptococci. (2) Otitis media due to group A ß-hemolytic streptococci,
S. pneumoniae, Haemophilus influenzae, and staphylococci. (3) Skin and skin structure infections due to staphylococci (penicillinase/nonpencilliase-producing) and ß- streptococci. (4) UTIs (including prostatitis) due to
Escherichia coli, Proteus mirabilis, and
Klebsiella species.
Parenteral. (1) Respiratory tract infections due to
S. pneumoniae, Klebsiella species,
H. influenzae, S. aureus (penicillinase/non-penicillinase-producing), and group A ß-hemolytic streptococci. (2) UTIs due to
E. coli, P. mirabilis, and
Klebsiella species. (3) Skin and skin structure infections due to
S. aureus and group A ß-hemolytic streptococci. (4) Bone infections due to
S. aureus. (5) Septicemia due to
S. pneumoniae, S. aureus, P. mirabilis, and
E. coli. (6) To prevent infections before, during, and after surgery for vaginal hysterectomy and other surgical procedures.
Special Concerns:
Safe use during pregnancy, of the parenteral form in infants under 1 month of age, and of the PO form in children less than 9 months of age have not been established.
Additional Laboratory Test Interferences:
False + reactions using sulfosalicylic acid for urinary protein tests. High concentrations may interfere with measurement of creatinine by the Jaffe method.
How Supplied:
Capsule: 250 mg, 500 mg;
Powder for Reconstitution: 125 mg/5 mL, 250 mg/5 mL
Dosage
?Capsules, Oral Suspension
Skin and skin structures, respiratory tract infections (other than lobar pneumonia).
Adults, usual: 250 mg q 6 hr or 500 mg q 12 hr.
Lobar pneumonia.
Adults: 500 mg q 6 hr or 1 g q 12 hr.
Uncomplicated UTIs.
Adults, usual: 500 mg q 12 hr.
More serious UTIs and prostatitis.
500 mg q 6 hr or 1 g q 12 hr (severe, chronic infections may require up to 1 g q 6 hr).
Use in children.
Pediatric, over 9 months: 25-50 mg/kg/day in equally divided doses q 6-12 hr (75-100 mg/kg/day for otitis media). Do not exceed 4 g/day.
?Deep IM, IV
General infections.
Adults: 2-4 g/day in equally divided doses q.i.d.
Surgical prophylaxis.
Adults: 1 g 30-90 min before surgery;
then, 1 g q 4-6 hr for one to two doses (or up to 24 hr postoperatively).
Cesarean section, prophylaxis.
IV: 1 g when the umbilical cord is clamped;
then, give two additional 1-g doses
IV or IM 6 and 12 hr after the initial dose.
Use in children.
Pediatric, over 1 year: 50-100 mg/kg/day in equally divided doses q.i.d. Do not exceed adult dose.
Note: For clients not on dialysis, use the following dosage in renal impairment: C
CR, over 20 mL/min: 500 mg q 6 hr; C
CR, 5-20 mL/min: 250 mg q 6 hr; C
CR, less than 5 mL/min: 250 mg q 12 hr. For those on chronic, intermittent hemodialysis, give 250 mg initially; repeat at 12 hr and after 36-48 hr.
|
